搜索
ss
ss
关于普米斯
About Us
918刘晓林

Xiaolin Liu (Co-founder, Chairman & CEO)

As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discovery, development and and launch of Tyvyt (sintilimab) on the Chinese market.
所属分类
Back To List
918刘晓林
产品描述
[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]

As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discovery, development and and launch of Tyvyt (sintilimab) on the Chinese market.

关键词:
the
and
of
than
as
more
r&d
antibody
in
扫二维码用手机看
未找到相应参数组,请于后台属性模板中添加
There is currently no content to display
Please add data record on website background.

Copyright © 2022 Biotheus Inc. All Rights Reserved  粤ICP备2021122492号